Enlivex Therapeutics Ltd. (ENLV) 10-Year Financial Performance & Capital Metrics

ENLV • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesAntibiotics & Bacterial Infections

AboutEnlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.Show more

Revenue $0
EBITDA -$15M +47.5%
Net Income -$15M +48.3%
EPS (Diluted) -0.73 +53.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -55.95% +16.3%
ROIC -45.58% +54.3%
Debt/Equity 0.02 -34.0%
Interest Coverage -1195.08 +43.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.8x book value

✗Weaknesses

✗Shares diluted 10.4% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM32.92%

EPS CAGR

10Y-

5Y-

3Y-

TTM42.42%

ROCE

10Y Avg-67.08%

5Y Avg-45.32%

3Y Avg-51.65%

Latest-56.85%

Peer Comparison

Antibiotics & Bacterial Infections

Name	Market Cap	Current Price	P/E Ratio	Net Margin	ROE	Debt/Equity
PLRZPolyrizon Ltd.	16.19M	15.54	31.08		-5.21%
TOVXTheriva Biologics, Inc.	7.49M	0.21	-0.01		-388.69%	0.08
CTXRCitius Pharmaceuticals, Inc.	17.79M	0.86	-0.14	-258.23%	-59.6%	0.00
ACXPAcurx Pharmaceuticals, Inc.	6.32M	2.69	-0.15		-0.25%
ITRMIterum Therapeutics plc	17.16M	0.32	-0.26	-69.13%
ANTXAN2 Therapeutics, Inc.	34.25M	1.25	-0.73		-56.29%
MCRBSeres Therapeutics, Inc.	137.33M	15.18	-0.80	15.37%	12.34%	6.65
PYPDPolyPid Ltd.	73.03M	4.39	-0.89		-10.39%	1.25

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	2.28M	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-1%	-	-	-
Cost of Goods Sold+	17K	25K	12K	121K	297K	286K	546K	777K	835K	545K
COGS % of Revenue	-	-	-	-	-	0.13%	-	-	-	-
Gross Profit+	-17K	-25K	-12K	-121K	-297K	-286K	-546K	-777K	-835K	-545K
Gross Margin %	-	-	-	-	-	-0.13%	-	-	-	-
Gross Profit Growth %	-2.4%	-0.47%	0.52%	-9.08%	-1.45%	0.04%	-0.91%	-0.42%	-0.07%	0.35%
Operating Expenses+	15.48M	15.87M	5.96M	5.3M	8.62M	9.79M	19.29M	25.8M	29.39M	14.99M
OpEx % of Revenue	-	-	-	-	-	4.3%	-	-	-	-
Selling, General & Admin	7.78M	6.99M	3.44M	937K	2.75M	3.6M	6.24M	6.7M	6.14M	4.91M
SG&A % of Revenue	-	-	-	-	-	1.58%	-	-	-	-
Research & Development	7.69M	8.88M	2.52M	4.25M	5.72M	6.09M	12.88M	18.69M	19.23M	10.13M
R&D % of Revenue	-	-	-	-	-	2.67%	-	-	-	-
Other Operating Expenses	0	0	0	0	145K	97K	167K	402K	4.02M	-48K
Operating Income+	-15.48M	-15.87M	-5.96M	-5.3M	-8.62M	-9.79M	-19.29M	-25.8M	-29.39M	-15.54M
Operating Margin %	-	-	-	-	-	-4.3%	-	-	-	-
Operating Income Growth %	-1.19%	-0.03%	0.62%	0.11%	-0.63%	-0.14%	-0.97%	-0.34%	-0.14%	0.47%
EBITDA+	-15.46M	-15.84M	-5.94M	-5.18M	-8.32M	-9.5M	-18.74M	-25.02M	-28.56M	-14.99M
EBITDA Margin %	-	-	-	-	-	-4.17%	-	-	-	-
EBITDA Growth %	-1.19%	-0.02%	0.62%	0.13%	-0.61%	-0.14%	-0.97%	-0.33%	-0.14%	0.48%
D&A (Non-Cash Add-back)	17K	25K	12K	121K	297K	286K	546K	777K	835K	545K
EBIT	-15.33M	-15.81M	-5.92M	-5.3M	-8.62M	-9.79M	-19.29M	-25.8M	-29.05M	-15.01M
Net Interest Income+	0	0	0	0	231K	219K	-208K	-4.43M	1.55M	1.06M
Interest Income	186K	90K	39K	138K	238K	225K	120K	835K	1.56M	1.07M
Interest Expense	0	0	0	0	7K	6K	328K	5.26M	14K	13K
Other Income/Expense	135K	-1.86M	-67K	1.06M	-765K	-2.04M	4.82M	-5.26M	327K	522K
Pretax Income+	-15.34M	-15.81M	-5.92M	-4.24M	-9.38M	-11.82M	-14.47M	-31.06M	-29.07M	-15.01M
Pretax Margin %	-	-	-	-	-	-5.19%	-	-	-	-
Income Tax+	24K	216K	28K	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1.01%	1%	1.16%	1%	1%	1%	1%	1%	1%
Net Income+	-15.37M	-16.02M	-5.95M	-4.9M	-9.38M	-11.82M	-14.47M	-31.06M	-29.07M	-15.01M
Net Margin %	-	-	-	-	-	-5.19%	-	-	-	-
Net Income Growth %	-1.19%	-0.04%	0.63%	0.18%	-0.91%	-0.26%	-0.22%	-1.15%	0.06%	0.48%
Net Income (Continuing)	-15.37M	-16.02M	-5.95M	-4.24M	-9.38M	-11.82M	-14.47M	-31.06M	-29.07M	-15.01M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-43.19	-40.29	-13.88	-10.63	-1.17	-1.05	-0.54	-2.31	-1.56	-0.73
EPS Growth %	-0.89%	0.07%	0.66%	0.23%	0.89%	0.1%	0.49%	-3.28%	0.32%	0.53%
EPS (Basic)	-43.19	-40.29	-14.35	-10.63	-1.17	-1.05	-0.54	-2.31	-1.56	-0.73
Diluted Shares Outstanding	355.76K	397.65K	428.24K	461.03K	8.65M	13.17M	17.86M	18.39M	18.57M	20.51M
Basic Shares Outstanding	355.76K	397.65K	414.2K	461.03K	8.65M	13.17M	17.86M	18.39M	18.57M	20.51M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	20.39M	10.54M	3.62M	10.28M	16.42M	38.12M	86.44M	52.33M	33.76M	25.99M
Cash & Short-Term Investments	7.29M	6.87M	3.53M	9.78M	12.01M	35.71M	84.13M	48.12M	27.32M	23.61M
Cash Only	7.29M	6.87M	3.53M	9.74M	3.95M	5.67M	11.2M	47.82M	813K	3.3M
Short-Term Investments	0	0	0	40K	8.06M	30.03M	72.93M	299K	26.51M	20.2M
Accounts Receivable	145K	52K	0	213K	-1.1M	0	1.09M	0	0	1.3M
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	1.5M	0	-12.2M	1.18M	0	0
Days Inventory Outstanding	-	-	-	-	1.84K	-	-	552.9	-	-
Other Current Assets	0	0	0	0	3.5M	1.17M	1.2M	0	5.11M	198K
Total Non-Current Assets+	124K	89K	426	757K	1.14M	2.24M	8.7M	15.31M	3.07M	1.69M
Property, Plant & Equipment	91K	71K	388	685K	1.06M	2.14M	8.22M	14.9M	2.58M	1.15M
Fixed Asset Turnover	-	-	-	-	-	1.06x	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	410K	0	0	0	0	0
Long-Term Investments	33K	11K	0	56K	76K	89K	3K	307K	308K	531K
Other Non-Current Assets	0	7K	38	16K	-329K	8K	482K	105K	179K	10K
Total Assets+	20.52M	10.63M	3.62M	11.03M	17.56M	40.36M	95.15M	67.64M	36.83M	27.69M
Asset Turnover	-	-	-	-	-	0.06x	-	-	-	-
Asset Growth %	-0.38%	-0.48%	-0.66%	2.05%	0.59%	1.3%	1.36%	-0.29%	-0.46%	-0.25%
Total Current Liabilities+	2.51M	1.93M	460K	1.13M	5.98M	4.37M	4.72M	6.61M	6.06M	3.8M
Accounts Payable	1.41M	32K	19K	173K	316K	463K	878K	1.95M	827K	811K
Days Payables Outstanding	30.32K	467.2	577.92	521.86	388.35	590.89	586.94	915.08	361.5	543.15
Short-Term Debt	0	0	0	0	0	0	0	0	0	235K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	639K	1.5M	403K	0	3.4M	1.17M	0	0	1.57M	-93K
Current Ratio	8.11x	5.46x	7.87x	9.09x	2.75x	8.72x	18.32x	7.92x	5.57x	6.84x
Quick Ratio	8.11x	5.46x	7.87x	9.09x	2.50x	8.72x	20.91x	7.74x	5.57x	6.84x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	70K	0	0	198K	298K	499K	5.39M	4.19M	686K	299K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	5.39M	4.19M	686K	299K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	70K	0	0	198K	0	499K	0	0	0	0
Total Liabilities	2.58M	1.93M	460K	1.33M	6.28M	4.87M	10.11M	10.8M	6.75M	4.1M
Total Debt+	0	0	0	0	123K	203K	617K	4.85M	1.03M	534K
Net Debt	-7.29M	-6.87M	-3.53M	-9.74M	-3.83M	-5.47M	-10.59M	-42.98M	219K	-2.77M
Debt / Equity	-	-	-	-	0.01x	0.01x	0.01x	0.09x	0.03x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-1231.29x	-1630.83x	-58.80x	-4.90x	-2099.64x	-1195.08x
Total Equity+	17.93M	8.7M	3.16M	9.71M	11.28M	35.49M	85.04M	56.84M	30.08M	23.59M
Equity Growth %	-0.42%	-0.51%	-0.64%	2.07%	0.16%	2.15%	1.4%	-0.33%	-0.47%	-0.22%
Book Value per Share	50.40	21.88	7.38	21.05	1.30	2.69	4.76	3.09	1.62	1.15
Total Shareholders' Equity	17.93M	8.7M	3.16M	9.71M	11.28M	35.49M	85.04M	56.84M	30.08M	23.59M
Common Stock	39K	45K	45K	396K	1.15M	1.65M	2.11M	2.12M	2.14M	2.69M
Retained Earnings	-23.79M	-39.81M	-45.75M	-16.29M	-25.67M	-37.5M	-51.97M	-83.03M	-112.09M	-127.11M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-22K	-40K	-1.5K	-2.25M	-1.3M	977K	1.1M	1.1M	1.1M	1.1M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-13.25M	-15.49M	-6.35M	-3.16M	-7.04M	-11.01M	-17.54M	-23.95M	-23.52M	-13.01M
Operating CF Margin %	-	-	-	-	-	-4.83%	-	-	-	-
Operating CF Growth %	-2%	-0.17%	0.59%	0.5%	-1.23%	-0.56%	-0.59%	-0.37%	0.02%	0.45%
Net Income	-15.37M	-16.02M	-5.95M	-4.24M	-9.38M	-11.82M	-14.47M	-31.06M	-29.07M	-15.01M
Depreciation & Amortization	17K	38K	64K	121K	206K	286K	546K	777K	835K	545K
Stock-Based Compensation	2.62M	700K	408K	1.01M	810K	670K	2.91M	2.71M	1.95M	0
Deferred Taxes	0	0	0	0	119K	0	-5.59M	0	0	0
Other Non-Cash Items	-18K	39K	7K	-132K	168K	167K	413K	2.81M	4.58M	2.68M
Working Capital Changes	-506K	-241K	-886K	83K	1.04M	-306K	-1.36M	804K	-1.82M	-1.22M
Change in Receivables	-786K	399K	567K	-130K	41K	1.82M	-1.25M	278K	608K	433K
Change in Inventory	0	0	-790K	0	-41K	-1.82M	1.25M	-278K	0	0
Change in Payables	234K	-712K	-681K	145K	114K	36K	442K	1.17M	-1.12M	-16K
Cash from Investing+	9.95M	8.98M	3.01M	-533K	-6.36M	-20.98M	-38.41M	62.52M	-25.97M	9.06M
Capital Expenditures	-48K	-18K	-2K	-461K	-193K	-1.02M	-1.63M	-8.12M	-236K	-103K
CapEx % of Revenue	-	-	-	-	-	0.45%	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	10M	9M	3.01M	-32K	1.55M	-19.96K	20.03M	9.71M	133K	2.29M
Cash from Financing+	36.78M	6.09M	8.05K	5.19M	8.31M	33.08M	60.98M	150K	360K	6.45M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	36.78M	0	0	0	599K	8.62M	7.81M	150K	0	2K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-13.3M	-15.5M	-6.35M	-3.62M	-7.23M	-12.03M	-19.17M	-32.08M	-23.76M	-13.11M
FCF Margin %	-	-	-	-	-	-5.28%	-	-	-	-
FCF Growth %	-1.97%	-0.17%	0.59%	0.43%	-1%	-0.66%	-0.59%	-0.67%	0.26%	0.45%
FCF per Share	-37.38	-38.99	-14.84	-7.86	-0.84	-0.91	-1.07	-1.74	-1.28	-0.64
FCF Conversion (FCF/Net Income)	0.86x	0.97x	1.07x	0.64x	0.75x	0.93x	1.21x	0.77x	0.81x	0.87x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	4K	210K	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-63.22%	-120.33%	-100.24%	-76.17%	-89.42%	-50.56%	-24.01%	-43.78%	-66.88%	-55.95%
Return on Invested Capital (ROIC)	-75.52%	-190.79%	-610.14%	-	-174.07%	-39.17%	-27.69%	-43.81%	-99.83%	-45.58%
Gross Margin	-	-	-	-	-	-12.56%	-	-	-	-
Net Margin	-	-	-	-	-	-519.28%	-	-	-	-
Debt / Equity	-	-	-	-	0.01x	0.01x	0.01x	0.09x	0.03x	0.02x
Interest Coverage	-	-	-	-	-1231.29x	-1630.83x	-58.80x	-4.90x	-2099.64x	-1195.08x
FCF Conversion	0.86x	0.97x	1.07x	0.64x	0.75x	0.93x	1.21x	0.77x	0.81x	0.87x
Revenue Growth	-	-	-	-	-	-	-100%	-	-	-

Frequently Asked Questions

Growth & Financials

Enlivex Therapeutics Ltd. (ENLV) grew revenue by 0.0% over the past year. Growth has been modest.

Enlivex Therapeutics Ltd. (ENLV) reported a net loss of $12.7M for fiscal year 2024.

Dividend & Returns

Enlivex Therapeutics Ltd. (ENLV) has a return on equity (ROE) of -55.9%. Negative ROE indicates the company is unprofitable.

Enlivex Therapeutics Ltd. (ENLV) had negative free cash flow of $12.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Enlivex Therapeutics Ltd. (ENLV) 10-Year Financial Performance & Capital Metrics

ENLV • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesAntibiotics & Bacterial Infections

Revenue $0
EBITDA -$15M +47.5%
Net Income -$15M +48.3%
EPS (Diluted) -0.73 +53.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -55.95% +16.3%
ROIC -45.58% +54.3%
Debt/Equity 0.02 -34.0%
Interest Coverage -1195.08 +43.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.8x book value

✗Weaknesses

✗Shares diluted 10.4% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM32.92%

EPS CAGR

10Y-

5Y-

3Y-

TTM42.42%

ROCE

10Y Avg-67.08%

5Y Avg-45.32%

3Y Avg-51.65%

Latest-56.85%

Peer Comparison

Antibiotics & Bacterial Infections

Name	Market Cap	Current Price	P/E Ratio	Net Margin	ROE	Debt/Equity
PLRZPolyrizon Ltd.	16.19M	15.54	31.08		-5.21%
TOVXTheriva Biologics, Inc.	7.49M	0.21	-0.01		-388.69%	0.08
CTXRCitius Pharmaceuticals, Inc.	17.79M	0.86	-0.14	-258.23%	-59.6%	0.00
ACXPAcurx Pharmaceuticals, Inc.	6.32M	2.69	-0.15		-0.25%
ITRMIterum Therapeutics plc	17.16M	0.32	-0.26	-69.13%
ANTXAN2 Therapeutics, Inc.	34.25M	1.25	-0.73		-56.29%
MCRBSeres Therapeutics, Inc.	137.33M	15.18	-0.80	15.37%	12.34%	6.65
PYPDPolyPid Ltd.	73.03M	4.39	-0.89		-10.39%	1.25

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	2.28M	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-1%	-	-	-
Cost of Goods Sold+	17K	25K	12K	121K	297K	286K	546K	777K	835K	545K
COGS % of Revenue	-	-	-	-	-	0.13%	-	-	-	-
Gross Profit+	-17K	-25K	-12K	-121K	-297K	-286K	-546K	-777K	-835K	-545K
Gross Margin %	-	-	-	-	-	-0.13%	-	-	-	-
Gross Profit Growth %	-2.4%	-0.47%	0.52%	-9.08%	-1.45%	0.04%	-0.91%	-0.42%	-0.07%	0.35%
Operating Expenses+	15.48M	15.87M	5.96M	5.3M	8.62M	9.79M	19.29M	25.8M	29.39M	14.99M
OpEx % of Revenue	-	-	-	-	-	4.3%	-	-	-	-
Selling, General & Admin	7.78M	6.99M	3.44M	937K	2.75M	3.6M	6.24M	6.7M	6.14M	4.91M
SG&A % of Revenue	-	-	-	-	-	1.58%	-	-	-	-
Research & Development	7.69M	8.88M	2.52M	4.25M	5.72M	6.09M	12.88M	18.69M	19.23M	10.13M
R&D % of Revenue	-	-	-	-	-	2.67%	-	-	-	-
Other Operating Expenses	0	0	0	0	145K	97K	167K	402K	4.02M	-48K
Operating Income+	-15.48M	-15.87M	-5.96M	-5.3M	-8.62M	-9.79M	-19.29M	-25.8M	-29.39M	-15.54M
Operating Margin %	-	-	-	-	-	-4.3%	-	-	-	-
Operating Income Growth %	-1.19%	-0.03%	0.62%	0.11%	-0.63%	-0.14%	-0.97%	-0.34%	-0.14%	0.47%
EBITDA+	-15.46M	-15.84M	-5.94M	-5.18M	-8.32M	-9.5M	-18.74M	-25.02M	-28.56M	-14.99M
EBITDA Margin %	-	-	-	-	-	-4.17%	-	-	-	-
EBITDA Growth %	-1.19%	-0.02%	0.62%	0.13%	-0.61%	-0.14%	-0.97%	-0.33%	-0.14%	0.48%
D&A (Non-Cash Add-back)	17K	25K	12K	121K	297K	286K	546K	777K	835K	545K
EBIT	-15.33M	-15.81M	-5.92M	-5.3M	-8.62M	-9.79M	-19.29M	-25.8M	-29.05M	-15.01M
Net Interest Income+	0	0	0	0	231K	219K	-208K	-4.43M	1.55M	1.06M
Interest Income	186K	90K	39K	138K	238K	225K	120K	835K	1.56M	1.07M
Interest Expense	0	0	0	0	7K	6K	328K	5.26M	14K	13K
Other Income/Expense	135K	-1.86M	-67K	1.06M	-765K	-2.04M	4.82M	-5.26M	327K	522K
Pretax Income+	-15.34M	-15.81M	-5.92M	-4.24M	-9.38M	-11.82M	-14.47M	-31.06M	-29.07M	-15.01M
Pretax Margin %	-	-	-	-	-	-5.19%	-	-	-	-
Income Tax+	24K	216K	28K	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1.01%	1%	1.16%	1%	1%	1%	1%	1%	1%
Net Income+	-15.37M	-16.02M	-5.95M	-4.9M	-9.38M	-11.82M	-14.47M	-31.06M	-29.07M	-15.01M
Net Margin %	-	-	-	-	-	-5.19%	-	-	-	-
Net Income Growth %	-1.19%	-0.04%	0.63%	0.18%	-0.91%	-0.26%	-0.22%	-1.15%	0.06%	0.48%
Net Income (Continuing)	-15.37M	-16.02M	-5.95M	-4.24M	-9.38M	-11.82M	-14.47M	-31.06M	-29.07M	-15.01M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-43.19	-40.29	-13.88	-10.63	-1.17	-1.05	-0.54	-2.31	-1.56	-0.73
EPS Growth %	-0.89%	0.07%	0.66%	0.23%	0.89%	0.1%	0.49%	-3.28%	0.32%	0.53%
EPS (Basic)	-43.19	-40.29	-14.35	-10.63	-1.17	-1.05	-0.54	-2.31	-1.56	-0.73
Diluted Shares Outstanding	355.76K	397.65K	428.24K	461.03K	8.65M	13.17M	17.86M	18.39M	18.57M	20.51M
Basic Shares Outstanding	355.76K	397.65K	414.2K	461.03K	8.65M	13.17M	17.86M	18.39M	18.57M	20.51M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	20.39M	10.54M	3.62M	10.28M	16.42M	38.12M	86.44M	52.33M	33.76M	25.99M
Cash & Short-Term Investments	7.29M	6.87M	3.53M	9.78M	12.01M	35.71M	84.13M	48.12M	27.32M	23.61M
Cash Only	7.29M	6.87M	3.53M	9.74M	3.95M	5.67M	11.2M	47.82M	813K	3.3M
Short-Term Investments	0	0	0	40K	8.06M	30.03M	72.93M	299K	26.51M	20.2M
Accounts Receivable	145K	52K	0	213K	-1.1M	0	1.09M	0	0	1.3M
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	1.5M	0	-12.2M	1.18M	0	0
Days Inventory Outstanding	-	-	-	-	1.84K	-	-	552.9	-	-
Other Current Assets	0	0	0	0	3.5M	1.17M	1.2M	0	5.11M	198K
Total Non-Current Assets+	124K	89K	426	757K	1.14M	2.24M	8.7M	15.31M	3.07M	1.69M
Property, Plant & Equipment	91K	71K	388	685K	1.06M	2.14M	8.22M	14.9M	2.58M	1.15M
Fixed Asset Turnover	-	-	-	-	-	1.06x	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	410K	0	0	0	0	0
Long-Term Investments	33K	11K	0	56K	76K	89K	3K	307K	308K	531K
Other Non-Current Assets	0	7K	38	16K	-329K	8K	482K	105K	179K	10K
Total Assets+	20.52M	10.63M	3.62M	11.03M	17.56M	40.36M	95.15M	67.64M	36.83M	27.69M
Asset Turnover	-	-	-	-	-	0.06x	-	-	-	-
Asset Growth %	-0.38%	-0.48%	-0.66%	2.05%	0.59%	1.3%	1.36%	-0.29%	-0.46%	-0.25%
Total Current Liabilities+	2.51M	1.93M	460K	1.13M	5.98M	4.37M	4.72M	6.61M	6.06M	3.8M
Accounts Payable	1.41M	32K	19K	173K	316K	463K	878K	1.95M	827K	811K
Days Payables Outstanding	30.32K	467.2	577.92	521.86	388.35	590.89	586.94	915.08	361.5	543.15
Short-Term Debt	0	0	0	0	0	0	0	0	0	235K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	639K	1.5M	403K	0	3.4M	1.17M	0	0	1.57M	-93K
Current Ratio	8.11x	5.46x	7.87x	9.09x	2.75x	8.72x	18.32x	7.92x	5.57x	6.84x
Quick Ratio	8.11x	5.46x	7.87x	9.09x	2.50x	8.72x	20.91x	7.74x	5.57x	6.84x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	70K	0	0	198K	298K	499K	5.39M	4.19M	686K	299K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	5.39M	4.19M	686K	299K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	70K	0	0	198K	0	499K	0	0	0	0
Total Liabilities	2.58M	1.93M	460K	1.33M	6.28M	4.87M	10.11M	10.8M	6.75M	4.1M
Total Debt+	0	0	0	0	123K	203K	617K	4.85M	1.03M	534K
Net Debt	-7.29M	-6.87M	-3.53M	-9.74M	-3.83M	-5.47M	-10.59M	-42.98M	219K	-2.77M
Debt / Equity	-	-	-	-	0.01x	0.01x	0.01x	0.09x	0.03x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-1231.29x	-1630.83x	-58.80x	-4.90x	-2099.64x	-1195.08x
Total Equity+	17.93M	8.7M	3.16M	9.71M	11.28M	35.49M	85.04M	56.84M	30.08M	23.59M
Equity Growth %	-0.42%	-0.51%	-0.64%	2.07%	0.16%	2.15%	1.4%	-0.33%	-0.47%	-0.22%
Book Value per Share	50.40	21.88	7.38	21.05	1.30	2.69	4.76	3.09	1.62	1.15
Total Shareholders' Equity	17.93M	8.7M	3.16M	9.71M	11.28M	35.49M	85.04M	56.84M	30.08M	23.59M
Common Stock	39K	45K	45K	396K	1.15M	1.65M	2.11M	2.12M	2.14M	2.69M
Retained Earnings	-23.79M	-39.81M	-45.75M	-16.29M	-25.67M	-37.5M	-51.97M	-83.03M	-112.09M	-127.11M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-22K	-40K	-1.5K	-2.25M	-1.3M	977K	1.1M	1.1M	1.1M	1.1M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-13.25M	-15.49M	-6.35M	-3.16M	-7.04M	-11.01M	-17.54M	-23.95M	-23.52M	-13.01M
Operating CF Margin %	-	-	-	-	-	-4.83%	-	-	-	-
Operating CF Growth %	-2%	-0.17%	0.59%	0.5%	-1.23%	-0.56%	-0.59%	-0.37%	0.02%	0.45%
Net Income	-15.37M	-16.02M	-5.95M	-4.24M	-9.38M	-11.82M	-14.47M	-31.06M	-29.07M	-15.01M
Depreciation & Amortization	17K	38K	64K	121K	206K	286K	546K	777K	835K	545K
Stock-Based Compensation	2.62M	700K	408K	1.01M	810K	670K	2.91M	2.71M	1.95M	0
Deferred Taxes	0	0	0	0	119K	0	-5.59M	0	0	0
Other Non-Cash Items	-18K	39K	7K	-132K	168K	167K	413K	2.81M	4.58M	2.68M
Working Capital Changes	-506K	-241K	-886K	83K	1.04M	-306K	-1.36M	804K	-1.82M	-1.22M
Change in Receivables	-786K	399K	567K	-130K	41K	1.82M	-1.25M	278K	608K	433K
Change in Inventory	0	0	-790K	0	-41K	-1.82M	1.25M	-278K	0	0
Change in Payables	234K	-712K	-681K	145K	114K	36K	442K	1.17M	-1.12M	-16K
Cash from Investing+	9.95M	8.98M	3.01M	-533K	-6.36M	-20.98M	-38.41M	62.52M	-25.97M	9.06M
Capital Expenditures	-48K	-18K	-2K	-461K	-193K	-1.02M	-1.63M	-8.12M	-236K	-103K
CapEx % of Revenue	-	-	-	-	-	0.45%	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	10M	9M	3.01M	-32K	1.55M	-19.96K	20.03M	9.71M	133K	2.29M
Cash from Financing+	36.78M	6.09M	8.05K	5.19M	8.31M	33.08M	60.98M	150K	360K	6.45M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	36.78M	0	0	0	599K	8.62M	7.81M	150K	0	2K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-13.3M	-15.5M	-6.35M	-3.62M	-7.23M	-12.03M	-19.17M	-32.08M	-23.76M	-13.11M
FCF Margin %	-	-	-	-	-	-5.28%	-	-	-	-
FCF Growth %	-1.97%	-0.17%	0.59%	0.43%	-1%	-0.66%	-0.59%	-0.67%	0.26%	0.45%
FCF per Share	-37.38	-38.99	-14.84	-7.86	-0.84	-0.91	-1.07	-1.74	-1.28	-0.64
FCF Conversion (FCF/Net Income)	0.86x	0.97x	1.07x	0.64x	0.75x	0.93x	1.21x	0.77x	0.81x	0.87x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	4K	210K	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-63.22%	-120.33%	-100.24%	-76.17%	-89.42%	-50.56%	-24.01%	-43.78%	-66.88%	-55.95%
Return on Invested Capital (ROIC)	-75.52%	-190.79%	-610.14%	-	-174.07%	-39.17%	-27.69%	-43.81%	-99.83%	-45.58%
Gross Margin	-	-	-	-	-	-12.56%	-	-	-	-
Net Margin	-	-	-	-	-	-519.28%	-	-	-	-
Debt / Equity	-	-	-	-	0.01x	0.01x	0.01x	0.09x	0.03x	0.02x
Interest Coverage	-	-	-	-	-1231.29x	-1630.83x	-58.80x	-4.90x	-2099.64x	-1195.08x
FCF Conversion	0.86x	0.97x	1.07x	0.64x	0.75x	0.93x	1.21x	0.77x	0.81x	0.87x
Revenue Growth	-	-	-	-	-	-	-100%	-	-	-

Frequently Asked Questions

Growth & Financials

Enlivex Therapeutics Ltd. (ENLV) grew revenue by 0.0% over the past year. Growth has been modest.

Enlivex Therapeutics Ltd. (ENLV) reported a net loss of $12.7M for fiscal year 2024.

Dividend & Returns

Enlivex Therapeutics Ltd. (ENLV) has a return on equity (ROE) of -55.9%. Negative ROE indicates the company is unprofitable.

Enlivex Therapeutics Ltd. (ENLV) had negative free cash flow of $12.3M in fiscal year 2024, likely due to heavy capital investments.